【犬の関節の痛み、1回の注射で最長3カ月】
骨関節炎の犬に、ZoetisのLenivia（izenivetmab）が英国で出た。神経成長因子（NGF）を抑える抗体で、1回の投与が最長3カ月もつ。
Zoetis、犬用鎮痛モノクローナル抗体「Lenivia」を英国で発売──単回投与で最長3カ月の骨関節炎疼痛緩和、投与間隔延長で治療継続を支援
stellanews.life/veterinary/1...
骨関節炎の犬に、ZoetisのLenivia（izenivetmab）が英国で出た。神経成長因子（NGF）を抑える抗体で、1回の投与が最長3カ月もつ。
Zoetis、犬用鎮痛モノクローナル抗体「Lenivia」を英国で発売──単回投与で最長3カ月の骨関節炎疼痛緩和、投与間隔延長で治療継続を支援
stellanews.life/veterinary/1...
Zoetis、犬用鎮痛モノクローナル抗体「Lenivia」を英国で発売──単回投与で最長3カ月の骨関節炎疼痛緩和、投与間隔延長で治療継続を支援
Zoetis UKは、犬の骨関節炎に伴う疼痛緩和を目的とした長時間作用型モノクローナル抗体製剤「Lenivia」（一般名：izenivetmab）を英国で発売した。単回皮下注射で最長3カ月間の効果持続を目指す設計という。
stellanews.life
September 29, 2026 at 5:15 AM
【犬の関節の痛み、1回の注射で最長3カ月】
骨関節炎の犬に、ZoetisのLenivia（izenivetmab）が英国で出た。神経成長因子（NGF）を抑える抗体で、1回の投与が最長3カ月もつ。
Zoetis、犬用鎮痛モノクローナル抗体「Lenivia」を英国で発売──単回投与で最長3カ月の骨関節炎疼痛緩和、投与間隔延長で治療継続を支援
stellanews.life/veterinary/1...
骨関節炎の犬に、ZoetisのLenivia（izenivetmab）が英国で出た。神経成長因子（NGF）を抑える抗体で、1回の投与が最長3カ月もつ。
Zoetis、犬用鎮痛モノクローナル抗体「Lenivia」を英国で発売──単回投与で最長3カ月の骨関節炎疼痛緩和、投与間隔延長で治療継続を支援
stellanews.life/veterinary/1...
If you have a dog, this article may be useful, particularly if your dog is receiving #Librela or #Lenivia, or if you are considering either treatment. #AntiNGF #Dogs #VetMed #DogArthritis #Bedinvetmab #Izenivetmab
doi.org/10.3389/fvet...
doi.org/10.3389/fvet...
Frontiers | A neurotrophic withdrawal hypothesis for multisystem adverse events associated with anti-NGF therapy for canine osteoarthritis pain
Post-marketing reports in dogs treated with bedinvetmab (Librela™, Zoetis), the first anti-nerve growth factor (NGF) monoclonal antibody approved for canine ...
doi.org
September 11, 2026 at 7:06 AM
If you have a dog, this article may be useful, particularly if your dog is receiving #Librela or #Lenivia, or if you are considering either treatment. #AntiNGF #Dogs #VetMed #DogArthritis #Bedinvetmab #Izenivetmab
doi.org/10.3389/fvet...
doi.org/10.3389/fvet...
Full dragon form for Lenivia looking very intimidating!
Supporter sketch for Neruma!
Supporter sketch for Neruma!
August 4, 2026 at 3:20 PM
Full dragon form for Lenivia looking very intimidating!
Supporter sketch for Neruma!
Supporter sketch for Neruma!
Some concept design art for Lenivia Rasker the Rogue! New D&D character and Stream Snatch for Neruma!
January 3, 2025 at 5:13 PM
Some concept design art for Lenivia Rasker the Rogue! New D&D character and Stream Snatch for Neruma!
#ZTS Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
https://www.stocktitan.net/news/ZTS/zoetis-launches-lenivia-izenivetmab-injection-in-canada-and-the-k0o6f73wmtw9.html
https://www.stocktitan.net/news/ZTS/zoetis-launches-lenivia-izenivetmab-injection-in-canada-and-the-k0o6f73wmtw9.html
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
Zoetis (NYSE: ZTS) announced the launch of Lenivia (izenivetmab injection) in Canada and European Union member states. Lenivia is a long-acting monoclonal antibody therapy targeting nerve growth factor (NGF), designed to provide up to three months of osteoarthritis pain management for dogs with a single subcutaneous injection.According to Zoetis, Lenivia showed sustained pain reduction from as early as Day 7 in a pivotal nine-month European field study. The product expands Zoetis’ osteoarthritis pain portfolio alongside Rimadyl, Trocoxil and Librela, supporting veterinarians and pet owners with an additional long-term pain management option for dogs.
www.stocktitan.net
July 15, 2026 at 12:30 PM
#ZTS Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
https://www.stocktitan.net/news/ZTS/zoetis-launches-lenivia-izenivetmab-injection-in-canada-and-the-k0o6f73wmtw9.html
https://www.stocktitan.net/news/ZTS/zoetis-launches-lenivia-izenivetmab-injection-in-canada-and-the-k0o6f73wmtw9.html
#ZTS Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
https://www.stocktitan.net/news/ZTS/zoetis-receives-european-commission-marketing-authorization-for-4obp13102suu.html
https://www.stocktitan.net/news/ZTS/zoetis-receives-european-commission-marketing-authorization-for-4obp13102suu.html
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis (NYSE: ZTS) announced on November 26, 2025 that the European Commission granted marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs.Lenivia is described as a long‑acting monoclonal antibody targeting nerve growth factor (NGF) that can reduce OA pain for three months with one injection. A nine‑month field study reported a safety profile with dogs showing increased mobility and decreased pain after one injection. Lenivia will join Librela (bedinvetmab) in Zoetis’ portfolio of OA pain therapies for dogs.
www.stocktitan.net
November 26, 2025 at 9:15 PM
#ZTS Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
https://www.stocktitan.net/news/ZTS/zoetis-receives-european-commission-marketing-authorization-for-4obp13102suu.html
https://www.stocktitan.net/news/ZTS/zoetis-receives-european-commission-marketing-authorization-for-4obp13102suu.html
#ZTS Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
https://www.stocktitan.net/news/ZTS/zoetis-receives-positive-opinion-from-cvmp-for-lenivia-izenivetmab-crgxnjzjteu3.html
https://www.stocktitan.net/news/ZTS/zoetis-receives-positive-opinion-from-cvmp-for-lenivia-izenivetmab-crgxnjzjteu3.html
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
Zoetis (NYSE: ZTS) announced the EMA CVMP has issued a positive opinion recommending marketing authorization for Lenivia (izenivetmab) to reduce pain from osteoarthritis in dogs.The European Commission is expected to decide in Q4 2025, and Zoetis anticipates commercial availability in the EU in 2026. Lenivia is a monoclonal antibody that binds a different site on nerve growth factor and is designed to reduce OA pain for three months with one injection. A nine-month field study reported increased mobility and decreased pain after one injection.
www.stocktitan.net
October 10, 2025 at 8:15 PM
#ZTS Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
https://www.stocktitan.net/news/ZTS/zoetis-receives-positive-opinion-from-cvmp-for-lenivia-izenivetmab-crgxnjzjteu3.html
https://www.stocktitan.net/news/ZTS/zoetis-receives-positive-opinion-from-cvmp-for-lenivia-izenivetmab-crgxnjzjteu3.html
Après une AMM en médecine vétérinaire, où en est-on des anti-NGF chez l’homme ?
Anti-NGF : un traitement de chien !
Cet automne, l’Agence européenne du médicament (EMA) s’est positionnée en faveur de la mise sur le marché d’un nouveau médicament indiqué contre les douleurs liées à l’arthrose : l’izenivetmab (Lenivia). Un anticorps monoclonal anti-NGF destiné… aux chiens.
www.lequotidiendumedecin.fr
January 31, 2026 at 3:01 PM
Après une AMM en médecine vétérinaire, où en est-on des anti-NGF chez l’homme ?
The #EuropeanCommission has granted marketing authorization for a single-injection drug for managing canine pain associated with osteoarthritis.
www.dvm360.com/view/long-ac...
#Zoetis @ec.europa.eu
www.dvm360.com/view/long-ac...
#Zoetis @ec.europa.eu
Long-acting drug for reducing canine OA pain receives European marketing authorization | dvm360
The single-injection monoclonal antibody (Lenivia) from Zoetis reduces OA pain in dogs for 3 months.
www.dvm360.com
December 1, 2025 at 5:32 PM
The #EuropeanCommission has granted marketing authorization for a single-injection drug for managing canine pain associated with osteoarthritis.
www.dvm360.com/view/long-ac...
#Zoetis @ec.europa.eu
www.dvm360.com/view/long-ac...
#Zoetis @ec.europa.eu
"Zoetis #$ZTS Launches Lenivia in Canada and the EU"
Like Librela, it is a monoclonal antibody for OA pain
But it is not Librela and is also longer-acting (3 months)
(Lenivia not yet launched in the US; US approval expected in 2027, per CFO at W. Blair conf. in Jun-26)
Like Librela, it is a monoclonal antibody for OA pain
But it is not Librela and is also longer-acting (3 months)
(Lenivia not yet launched in the US; US approval expected in 2027, per CFO at W. Blair conf. in Jun-26)
July 15, 2026 at 2:14 PM
"Zoetis #$ZTS Launches Lenivia in Canada and the EU"
Like Librela, it is a monoclonal antibody for OA pain
But it is not Librela and is also longer-acting (3 months)
(Lenivia not yet launched in the US; US approval expected in 2027, per CFO at W. Blair conf. in Jun-26)
Like Librela, it is a monoclonal antibody for OA pain
But it is not Librela and is also longer-acting (3 months)
(Lenivia not yet launched in the US; US approval expected in 2027, per CFO at W. Blair conf. in Jun-26)
Zoetis receives positive CVMP opinion on Lenivia (long-acting monoclonal antibody for OA pain in dogs)
Expecting EU approval in Q4, commercial launch in '26
Already announced similar positive opinion on Portela, long-acting mAb for OA pain in cats, on 12-Sep
$ZTS $ELAN
Expecting EU approval in Q4, commercial launch in '26
Already announced similar positive opinion on Portela, long-acting mAb for OA pain in cats, on 12-Sep
$ZTS $ELAN
October 13, 2025 at 8:24 AM
Zoetis receives positive CVMP opinion on Lenivia (long-acting monoclonal antibody for OA pain in dogs)
Expecting EU approval in Q4, commercial launch in '26
Already announced similar positive opinion on Portela, long-acting mAb for OA pain in cats, on 12-Sep
$ZTS $ELAN
Expecting EU approval in Q4, commercial launch in '26
Already announced similar positive opinion on Portela, long-acting mAb for OA pain in cats, on 12-Sep
$ZTS $ELAN
💵 #Forex
"Up to 40% of dogs may have radiographic osteoarthritis – New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection PARSIPPANY, N.J. — Zoetis Inc. (NYSE: ZTS) today announced that it has recently…"
"Up to 40% of dogs may have radiographic osteoarthritis – New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection PARSIPPANY, N.J. — Zoetis Inc. (NYSE: ZTS) today announced that it has recently…"
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
financialpost.com
July 15, 2026 at 1:22 PM
Zoetis lanza Lenivia®, una nueva terapia de acción prolongada para la osteoartritis canina
Zoetis lanza Lenivia®, una nueva terapia de acción prolongada para la osteoartritis canina
Zoetis amplía su cartera para el manejo del dolor por osteoartritis en perros con el lanzamiento de Lenivia®, un nuevo anticuerpo monoclonal de acción prolongada que ya está disponible en Ca ...
www.diarioveterinario.com
July 15, 2026 at 12:53 PM
Zoetis lanza Lenivia®, una nueva terapia de acción prolongada para la osteoartritis canina
"Nos complace presentar Lenivia® como nuestra primera terapia de acción prolongada que reduce el dolor de la #osteoartritis en perros, lo que mejora la calidad de vida y la movilidad"
Europa autoriza la comercialización de Lenivia® de Zoetis para reducir el dolor de osteoartritis en perros
Lenivia® de Zoetis es una nueva terapia con anticuerpos que reduce el dolor por artrosis en perros durante tres meses con una sola inyección ...
mlibr.es
November 30, 2025 at 6:02 PM
"Nos complace presentar Lenivia® como nuestra primera terapia de acción prolongada que reduce el dolor de la #osteoartritis en perros, lo que mejora la calidad de vida y la movilidad"
Lenivia® de Zoetis es una nueva terapia con anticuerpos que reduce el dolor por artrosis en perros durante tres meses con una sola inyección.
Europa autoriza la comercialización de Lenivia® de Zoetis para reducir el dolor de osteoartritis en perros
Lenivia® de Zoetis es una nueva terapia con anticuerpos que reduce el dolor por artrosis en perros durante tres meses con una sola inyección ...
www.diarioveterinario.com
November 28, 2025 at 11:03 AM
Lenivia® de Zoetis es una nueva terapia con anticuerpos que reduce el dolor por artrosis en perros durante tres meses con una sola inyección.
Europa autoriza la comercialización de Lenivia® de Zoetis para reducir el dolor de #osteoartritis en #perros
Europa autoriza la comercialización de Lenivia® de Zoetis para reducir el dolor de osteoartritis en perros
Lenivia® de Zoetis es una nueva terapia con anticuerpos que reduce el dolor por artrosis en perros durante tres meses con una sola inyección ...
www.diarioveterinario.com
November 27, 2025 at 7:20 AM
Europa autoriza la comercialización de Lenivia® de Zoetis para reducir el dolor de #osteoartritis en #perros